Researchers have developed a new cervical cancer screening test, which could double the rate of early diagnosis.

The ZedScan, developed by an expert British doctor, found that it caused minor changes in the cells of the uterus before it became cancerous.

This means that women can be treated more quickly and more effectively, leading to a reduction in the number of deaths from the deadly disease.

The study involved 1,200 women who underwent a range of tests, known as vaginoscopy, after detecting abnormal deformation.

The “ZedScan” test, in the less serious cases, identified an additional 50% condition in which potential “cancerous” cells existed, compared with vaginal endoscopy alone. The trials also received an additional 13% of the cases in which more advanced cells existed before they became cancerous.

“It is important that the test becomes more sensitive and effective, because the HPV vaccine, introduced to girls aged 12 and 13 years in 2008, means that while it will be,” said John Teddy, a professor of oncology at Sheffield Teaching Hospitals who developed the device, There are fewer cases of cervical cancer in the future, it is likely to be difficult to detect.

HPV is associated with cervical cancer in about 99.7% of cases. “The virus vaccine protects women from two strains of infection, which are associated with most cases of cervical cancer and pre-cancer, but other strains can still cause abnormal changes in the cervix, being less easily detectable,” Professor Teddy said.

Beginning next year, women will be tested for sexually transmitted human papillomavirus (HPV) for the first time. If the results are positive, the same samples will be examined for abnormal cells. This creates the possibility of identifying situations at risk.